Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy (RA-TLH)
Pain, Postoperative
About this trial
This is an interventional treatment trial for Pain, Postoperative focused on measuring Hysterectomy
Eligibility Criteria
Inclusion Criteria:
- Women undergoing robotic-assisted total laparoscopic hysterectomy, with or without bilateral salpingo-oophorectomy
- Uterine weight ≤325 grams
Exclusion Criteria:
- contraindication to any study medications (h/o gastric bypass, gastric ulcers, CKD)
- current opioid prescription
Sites / Locations
- Millard Fillmore Suburban Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Prospective cohort
Historical Control
Pre-Op: Gabapentin 600mg PO PO x 1 prior to surgery (in pre-op) Acetaminophen 1000mg PO x1 prior to surgery (in pre-op) Intra-Op: Paracervical block with local anesthetic (0.5% ropivacaine); 10 mL bilaterally (2 point) for total of 20mL Local anesthetic (0.5% ropivacaine) at all laparoscopic port sites; another 10mL Will operate at <15mmHg intra-abdominal pressure, with goal of <12mmHg At end of procedure during closure of fascia, give 30mg ketorolac IV x 1 Post-Op: Gabapentin 300mg PO BID for 7 days Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN Celecoxib 200mg PO q 12h x 7d Dilaudid 1mg IV PRN q3h while inpatient; oxycodone 12 x 5mg upon discharge (90MME) if patient did not use any opioids postoperatively while inpatient, will not prescribe opioid medication upon discharge
Traditional post-operative opioid medication regimen: Dilaudid 1mg IV PRN q3h while inpatient; Percocets 12 x 5mg/325 (90MME) upon discharge